On Monday, Elixirgen Therapeutics and its research collaborators will present data from the company’s lead candidate, EXG-34217, a first-in-human cell therapy that aims to extend telomere length in patients with telomere biology disorders.

While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger.

Theseus’ pan-variant inhibitor candidates are designed to outsmart cancer treatment resistance by precluding that “arms race.” Pan-variant inhibitors are single therapeutic agents that maintain their anti-cancer activity against a target protein in the face of any and all major classes of cancer-causing and resistance mutations.

PepGen was one of a handful of biotech companies to go public this year, tapping into capital markets despite high inflation and economic conditions that have leading analysts predicting a global recession throughout 2023.

The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a recording derived from chemotherapy drug paclitaxel. We caught up with EMulate’s CEO Chris Rivera to find out more.

When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking:

“The Portage model has the same goal, which is to get to human proof-of-concept as quickly as possible,” says Walters. “

“We’re in a steel mill town,” Keir Loiacono, chief executive officer at BlueSphere Bio told BioSpace. “I can look from my office out of the glass buildings and see coal barges going through, right next to young scientists in lab coats. It’s the old and the new – it’s everybody working together.”